Topic: Advances in Electrochemotherapy and Other Treatments for Triple-Negative Breast Cancer
A Special Issue of Journal of Cancer Metastasis and Treatment
ISSN 2454-2857 (Online) 2394-4722 (Print)
Submission deadline: 30 Jun 2024
Guest Editor(s)
Special Issue Introduction
Aim: The Special Issue of Journal of Cancer Metastasis and Treatment aims to explore cutting-edge advancements in the treatment of Triple-Negative Breast Cancer (TNBC) through Electrochemotherapy (ECT) and other innovative therapeutic modalities while shedding light on promising avenues for improving outcomes in TNBC patients.
Introduction: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that lacks expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). This unique profile renders TNBC less responsive to traditional hormone-targeted and HER2-targeted therapies, resulting in a poorer prognosis compared to other subtypes of breast cancer.
Electrochemotherapy (ECT): ECT represents a locoregional treatment technique that combines the administration of a chemotherapeutic agent with the application of electric pulses at the tumor site. The electric pulses create temporary pores in the cell membrane, amplifying the absorption of chemotherapeutic agents into cells more effectively. ECT has been shown to be an effective treatment for TNBC, with response rates of up to 80% in some studies.
Advances in Electrochemotherapy:
The spotlight of this Special Issue is on Electrochemotherapy, a novel approach that combines chemotherapy with electroporation to enhance drug delivery into cancer cells. Contributions are invited to delve into mechanistic insights, preclinical studies, and clinical trials evaluating the efficacy of Electrochemotherapy in TNBC. Additionally, discussions on optimizing treatment protocols, identifying predictive biomarkers, and addressing potential challenges in implementing Electrochemotherapy related to electrode geometry, thickness, number, and length of needles, as well as the material used, are encouraged.
Other Treatments for Triple-Negative Breast Cancer:
List of various emerging treatments for TNBC, including but not limited to:
● 3D Scaffolds for TNBC Treatment: Utilizing 3D scaffolds as a delivery system for chemotherapeutic agents or as a platform for cancer cell culture in TNBC treatment.
● Immunotherapy Strategies: Investigating the role of immunotherapeutic agents, such as immune checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines, in the context of TNBC treatment.
● Targeted Therapies: Exploring the potential of targeted therapies that aim to exploit specific molecular pathways unique to TNBC, with an emphasis on precision medicine approaches.
● Nanotechnology-Based Approaches: Assessing the application of nanotechnology in drug delivery, imaging, and diagnostics for TNBC, highlighting advancements in nanoparticle-based therapies.
● Radiation Therapy Innovations: Examining novel radiation therapy techniques, fractionation schedules, and combination strategies to optimize the therapeutic ratio for TNBC patients.
● Metabolic Interventions: Investigating interventions targeting the altered metabolic pathways in TNBC, including studies on metabolic inhibitors, dietary interventions, and metabolic imaging.
Biomarker Discovery: Contributing research on identifying and validating predictive and prognostic biomarkers for TNBC, facilitating personalized treatment approaches.
● Proteomics: Proteomic studies identifying several proteins that are differentially expressed in TNBC compared to other subtypes of breast cancer. These proteins may serve as potential biomarkers for TNBC and may also be targets for new therapies.
Introduction: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that lacks expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). This unique profile renders TNBC less responsive to traditional hormone-targeted and HER2-targeted therapies, resulting in a poorer prognosis compared to other subtypes of breast cancer.
Electrochemotherapy (ECT): ECT represents a locoregional treatment technique that combines the administration of a chemotherapeutic agent with the application of electric pulses at the tumor site. The electric pulses create temporary pores in the cell membrane, amplifying the absorption of chemotherapeutic agents into cells more effectively. ECT has been shown to be an effective treatment for TNBC, with response rates of up to 80% in some studies.
Advances in Electrochemotherapy:
The spotlight of this Special Issue is on Electrochemotherapy, a novel approach that combines chemotherapy with electroporation to enhance drug delivery into cancer cells. Contributions are invited to delve into mechanistic insights, preclinical studies, and clinical trials evaluating the efficacy of Electrochemotherapy in TNBC. Additionally, discussions on optimizing treatment protocols, identifying predictive biomarkers, and addressing potential challenges in implementing Electrochemotherapy related to electrode geometry, thickness, number, and length of needles, as well as the material used, are encouraged.
Other Treatments for Triple-Negative Breast Cancer:
List of various emerging treatments for TNBC, including but not limited to:
● 3D Scaffolds for TNBC Treatment: Utilizing 3D scaffolds as a delivery system for chemotherapeutic agents or as a platform for cancer cell culture in TNBC treatment.
● Immunotherapy Strategies: Investigating the role of immunotherapeutic agents, such as immune checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines, in the context of TNBC treatment.
● Targeted Therapies: Exploring the potential of targeted therapies that aim to exploit specific molecular pathways unique to TNBC, with an emphasis on precision medicine approaches.
● Nanotechnology-Based Approaches: Assessing the application of nanotechnology in drug delivery, imaging, and diagnostics for TNBC, highlighting advancements in nanoparticle-based therapies.
● Radiation Therapy Innovations: Examining novel radiation therapy techniques, fractionation schedules, and combination strategies to optimize the therapeutic ratio for TNBC patients.
● Metabolic Interventions: Investigating interventions targeting the altered metabolic pathways in TNBC, including studies on metabolic inhibitors, dietary interventions, and metabolic imaging.
Biomarker Discovery: Contributing research on identifying and validating predictive and prognostic biomarkers for TNBC, facilitating personalized treatment approaches.
● Proteomics: Proteomic studies identifying several proteins that are differentially expressed in TNBC compared to other subtypes of breast cancer. These proteins may serve as potential biomarkers for TNBC and may also be targets for new therapies.
Keywords
Triple-negative breast cancer, electrochemotherapy, immunotherapy, targeted therapy, nanotechnology, radiation therapy, metabolic interventions, biomarkers, precision medicine
Submission Deadline
30 Jun 2024
Submission Information
For Author Instructions, please refer to https://www.oaepublish.com/jcmt/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=jcmt&SpecialIssueId=jcmt20231031
Submission Deadline: 30 Jun 2024
Contacts: Wendy Liu, Assistant Editor, wendy@oaeservice.com
